Examining the Impact of the FLAURA Trial in EGFR-Mutant NSCLC
Zofia Piotrowska, MD, MHS, discusses the rationale for conducting the FLAURA trial in patients with <em>EGFR</em>-mutant non–small cell lung cancer and how the use of osimertinib impacted the treatment landscape for this patient population.
Zofia Piotrowska, MD, MHS, a medical oncologist at Massachusetts General Hospital and an instructor at Harvard Medical School, discusses the rationale for conducting the FLAURA trial in patients withEGFR-mutant nonsmall cell lung cancer (NSCLC) and how the use of osimertinib (Tagrisso) impacted the treatment landscape for this patient population.
FLAURA was a large randomized phase III trial that was conducted in multiple countries. It aimed to answer the question of which EGFR inhibitor is best for frontline use in patients withEGFR-mutant NSCLC. At the time the study was conducted, first- and second-generation EGFR inhibitors were the standard of care, but Piotrowska says many patients who progressed on these drugs went on to develop theT790Mresistance mutations in EGFR.
For these patients, osimertinib appeared to work as an excellent second-line option. The agent had a great safety profile, says Piotrowska, as well as low rates of diarrhea and rash. The agent also had good central nervous system penetration, so all of this activity led investigators to wonder if it would be a better option in the first-line setting.
<< View more resources and information regarding EGFR-positive lung cancer
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
